drugset / Trial / NCT03238495
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the efficacy of metformin as a repurposed agent in human epidermal growth factor receptor 2 (HER2) positive breast cancer when added to standard neo-adjuvant chemotherapy.
Timeline
- Start
- 2017-08-15
- Primary completion
- 2022-06-01
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 850 mg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | Pertuzumab | Monoclonal antibody | 420 mg | — |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |